Uncategorized

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has determined its first two indications in non-small cell lung cancer (NSCLC) in which to pursue Phase III clinical trials for its innovative, potential first-in-class bispecific antibody, ivonescimab.

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112) Read More »

Rubedo Life Sciences Announces Nomination of First-in-Class Disease-Modifying Candidate RLS-1496 in Dermatology at LSX World Congress 2023

Rubedo Life Sciences today announced the selection of the first-in-class development candidate RLS-1496 for the treatment of dermatological conditions using its ALEMBIC™ drug discovery platform at LSX World Conference 2023.

Rubedo Life Sciences Announces Nomination of First-in-Class Disease-Modifying Candidate RLS-1496 in Dermatology at LSX World Congress 2023 Read More »

Scroll to Top